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actual invasion-inhibitory interaction of PHSCN with  integrin involves a noncovalent interaction with the target site, which is promoted by including D-isomers of histidine and cysteine in the PhScN peptide. Thus, covalent, disulfide bond formation withintegrin is actually a side reaction that decreases potency. Because mammalian proteins do not contain D-amino acids, endoproteinses evolved to cleave between Lamino acids only. Since PhScN does not contain 2 linked L-amino acids, it cannot be degraded by endoproteases, usually present at high levels in tumors and increasing with malignancy [6] [7] [8] . Thus, in addition to promoting noncovalent interaction with its  integrin target, the inclusion of D-amino acids at alternate positions likely results in increased PhScN potency as a result of preventing endoproteolytic degradation. Finally, the in vivo lung extravasation and colonization data, as well as the bone colony progression data presented in Figures 3, 4 , and 5, show that systemic PhScN therapy is a highly effective, well-tolerated systemic mono-therapy for reducing lung colonization and metastasis progression, as well as intratibial progression by metastatic breast cancer. The figures and tables presented in this annual report are listed below. Figure 1 . Hill-Slope plots of increased invasion-inhibitory potency of Ac-PhScN-NH 2 , Ac-PhScNGGK-MAP, and the cysteine-modified, methylated (Me) or acetylated (O-Ac) peptides for MDA-MB-231 cells. Table 3 . Extravasation Inhibition IC50's and DRI's: PhScN, PHSCN, and PhScNGGK-dendrimer, cN-MAP. Table 4 . Effects of PhScN or PHSCN pretreatment on lung colonization. Figure 7 . TIC (total ion current) chromatogram from an LC-MSMS of PHSCN and MRFA mixture. Figure 8 . CID (collision-induced dissociation) fragmentation of doubly-charged ion at 597.73 m/z. Fragment ions B4, A2, Y2,Y3, and Y4 containing S-S cross-linked peptides confirm S-S bond formation between two thiols of cysteine. BODY: Increased invasion inhibitory potency of Ac-PhScN-NH 2, and the Ac-PhScNGGK-MAP dendrimer.
The Hill-Slope plots for the effects of varying concentrations of Ac-PhScN-NH 2 , Ac-PHSC(S-OAc)N-NH 2 or Ac-PHSC(S-Me)N-NH 2 on MDA-MB-231 breast cancer cell invasion in vitro are shown in Figure 1A . Similar Hill-Slope plots were obtained for SUM149PT, as summarized in Table 1 . Moreover, to demonstrate that PhScN targets-mediated invasion specifically, we also utilized a peptide consisting of the  -specific ligand 16 ) from the ninth module of the fibronectin cell-binding domain, Ac-PHSRN-NH 2 (PHSRN) to induce invasion under serum-free conditions, as shown in Figure 1B . Table 1 summarizes the half maximal invasion inhibitory concentration (IC 50 ) and the dose reduction index (DRI) values for PHSCN and its S-methylated [C(Me)N] or S-acetylated [C(O-Ac)N} cysteine derivatives for both MDA-MB-231 and SUM149PT cell lines. IC 50 and DRI values based on pg/ml or molar (M) concentrations are also presented for Ac-PhScN-NH 2 (PhScN) and the Ac-PhScNGGK-MAP polylysine dendrimer (cN-MAP) for invasion induced by either serum or PHSRN, under serum-free conditions. As shown here, PhScN was a highly potent inhibitor of serum-free, PHSRN-induced invasion by both MDA-MB-231 and SUM149PT cells. These results demonstrate that PhScN targets -mediated invasion specifically in both cell lines. During the development of PHSCN for clinical trials, it was suggested that PHSCN inhibits invasion via disulfide bonding with  integrin 1 . However, the increased potencies of the S-acetylated or S-methylated PHSCN derivatives, Ac-PHSC(S-OAc)N-NH 2 or Ac-PHSC(S-Me)N-NH 2 , observed for both MDAMB231 and SUM149PT cells, and also seen in prostate cancer cell lines 17 , suggests that the productive mechanism is actually noncovalent; thus, covalent bonding is an unproductive side reaction. The similarity of the invasioninhibitory potency of the PhScN peptide to that of S-acetylated or S-methylated PHSCN further suggests that the substitutions of L-His with its stereoisomer D-His, and L-Cys with its stereoisomer D-Cys accomplish the same goal as covalent modification of the cysteine side chain, i.e. the prevention of disulfide bond formation. Hence the mechanism of inhibition for both PhScN and PHSCN is noncovalent 17 .
The PhScNGGK-MAP (7500) polylysine dendrimer consisting of 8 subunits of PhScN was also tested and demonstrated an astonishing 10 7 -fold increased invasion-inhibitory potency over monomeric PhScN (596 Da). This increase was significantly greater than the 1000-fold increase seen when comparing PHSCNGGK-MAP and PHSCN peptide 12, 13 , as shown above in Table 1 . This greatly increased potency demonstrates the potential for creating a multivalent peptide mimetic.
Comparison of dissociation constants (K d ) and competition binding assays for cell surface binding using biotinylated PhScN or PHSCN peptides
The composition of the PHSCN and PhScN peptides is chemically the same; however the Dstereoisomer amino acid substitutions produce differences in the orientation of the side chains on the peptide backbone. These differences could influence the binding of the compound to its target and also help explain the 100,000-fold increase in the PhScN invasion-inhibitory potency.
A binding assay using biotin-labeled PHSCN was developed during preparation for clinical trials 1 . This assay allows for determination of the dissociation constant (K d ) of a biotin-labeled peptide to suspended cells. Biotinylated derivatives of PHSCN and PhScN were obtained and first evaluated for inhibitory potency in the SU-ECM in vitro invasion assay. The IC 50 's of the new compounds, Ac-PhScNGGK-Bio and Ac-PHSCNGGK-Bio were found to be very similar to those of the parental Ac-PhScN-NH 2 and Ac-PHSCN-NH 2 peptides for both suspended MDA-MB-231 cells (Figure 2A , Table 2 ) and SUM149PT cells ( Table 2 ). Hence, the presence of the additional -GGK residues and the biotin moiety did not adversely affect the invasioninhibitory potencies in MDA-MB-231 and SUM149PT cells.
As shown in Figure 2B and summarized in Table 2 , the dissociation constant (K d ) values for thew Ac-PHSCNGGK-Bio binding to suspended SUM149PT and MDA-MB-231 cells were estimated to be 0.028 and 0.032 M, respectively. The K d values for Ac-PhScNGGK-Bio were estimated to be 0.029 and 0.053 M for suspended SUM 149PT and MDA-MB-231 cells, respectively. The values are very similar for both PHSCN and PhScN, thereby supporting the hypothesis that the improved invasion-inhibitory potency of PhScN (Table  1) is due to the elimination of the nonproductive covalent side reaction, rather than to tighter binding as a result of orienting the D-cysteine side chain to the opposite side of the peptide ligand. This is also consistent with our observations for metastatic prostate cancer cell lines 17 , and demonstrates that the noncovalent interaction is the key to invasion-inhibitory efficacy.
Competition assays were also performed to confirm that PHSCN and PhScN interact with the same binding site in breast cancer cells, as was found for DU 145 and PC-3 prostate cancer cells 17 . Results of competition assays, in which suspended MDA-MB-231 cells were incubated with a constant concentration (0.1 M) of biotinylated Ac-PHSCNGGK-Bio and varying concentrations of unlabeled Ac-PhScN-NH 2 , are presented in Fig. 2C . These results show that the dissociation of Ac-PHSCNGGK-Bio with increasing concentrations of unlabeled Ac-PhScN-NH 2 occurs over approximately 2 orders of magnitude, and demonstrates that PhScN and PHSCN are competing for the same binding site on MDA-MB-231 cells 18 . Similar results were obtained for SUM149PT, data not shown. 
Increased potencies of the PhScN peptide and PhScNGGK-MAP dendrimer as inhibitors of lung extravasation
Extravasation of tumor cells to the lung and successful colonization are late stages in breast cancer progression that are ultimately fatal. Hence, prevention of extravasation which leads to colony formation would increase life expectancy. Cell surface  integrin has been shown to play a key role in extravasation 17 . Furthermore, PHSCN has been shown to inhibit -mediated invasion specifically 1,4,,12,13,19-22 , and to reduce or prevent lung metastasis in preclinical models 1, 4,,12,13,17, 19-22 . Moreover, systemic PHSCN(ATN-161) was found to be well-tolerated, and to delay disease progression for 4 to 14 months in Phase I clinical trial 23 . Since Ac-PhScN-NH 2 exhibited a 100,000-fold greater inhibitory potency in vitro, on naturally occurring basement membranes 17 , we compared the efficacies of PhScN and PhScNGGK-MAP with the PHSCN peptide as inhibitors of lung extravasation by breast cancer cells in athymic mice.
To assess their efficacies, treatment groups-each consisting of 10 mice-received a single systemic pretreatment with the appropriate peptide or dendrimer concentrations by tail vein injection. Then, DiI-labeled MDA-MB-231 or SUM149PT cells, briefly prebound to the appropriate concentrations of peptide, were injected into the tail veins of the pretreated mice. The lungs were extracted 24 hours later. A graph of the mean number of extravasated cells per section, and the resulting dose response curves for inhibition of SUM149PT and MDA-MB-231 lung extravasation are presented in Figures 3A and 3B , respectively; and the IC 50 and DRI values are summarized in Table 3 . Each point shows the mean and SEM obtained from confocal microscopy analysis of 20 sections of 10 micron thickness, each separated by 200 microns, from each of a total of 10 mice for each treatment group. Figure 3C shows typical examples of sectioned lung tissue for MDA-MB-231 extravasation analyzed by confocal microscopy after pretreatment with 100 ng/ml Ac-PhScN-NH 2 or 100 ng/ml Ac-PHSCN-NH 2, compared to untreated control. Figure 3D shows typical examples of sectioned lung tissue for SUM149PT extravasation analyzed by confocal microscopy after pretreatment with 100 ng/ml Ac-PhScN-NH 2 or 100 ng/ml Ac-PHSCN-NH 2 , compared to untreated control. Images represent the merged composite of fluorescent DiI-labeled cells shown in orange; fluorescent blue-stained nuclei from DAPI-containing mounting medium; and fluorescent green anti-actin staining of cytoplasm. Lung extravasated MDA-MB-231 and SUM149PT cells had very similar appearance, as shown in Figs. 3C and 3D. The median-affect plots of Fig. 3B show that increasing concentrations of the PhScN or PHSCN peptides, or the PhScNGGK-MAP dendrimer, decrease SUM149PT and MDA-MB-231 extravasation in a log-linear fashion, with similar relative potencies in -hSPNc-NH 2 scrambled sequence control, followed by a single systemic treatment at the equivalent dose, had no inhibitory effect on lung extravasation, data not shown. As shown In Table 3 , the PhScN peptide appears to be 100-to 1000-fold more potent than the PHSCN peptide at inhibiting lung extravasation by both SUM149PT and MDA-AB-231 cells. Moreover, the PhScNGGK-MAP dendrimer appears to be 100,000-to 1,000,000-fold more potent than PHSCN at inhibiting lung extravasation by SUM149PT and MDA-MB-231 (Table 3 ). These in vivo values correlate well with those seen in the in vitro invasion assay (Table 1) using isolated, naturally occurring basement membranes. Increased potency of the PhScN peptide as an inhibitor of lung colonization Since extravasated cancer cells may be limited in their ability to establish a metastatic colony 24 , effects of PhScN or PHSCN pretreatment on subsequent lung colony formation were also evaluated after extravasated cells were allowed to grow in vivo without further treatment for 6 weeks. Figure 4A presents a comparison of the efficacies of prebinding various concentrations of PhScN or PHSCN to suspended, DiI-labeled SUM149PT or MDA-MB-231 cells on lung colonization after tail vein injection. The dose response curves are presented as median effect plots in Fig 4B, and the IC 50 and DRI values are summarized in Table 4 . Each value represents the mean and SEM from a total of 20 sections of 10 micron thickness, each separated by 200 microns, from each of 10 mice per treatment group. Figure 4C shows typical examples of DiI-labeled MDA-MB-231 lung colonies in fluorescent actin-and DAPI-stained lung tissue after no treatment, and after prebinding of the injected cells to 100 ng/ml of either PHSCN or PhScN. DiI-labeled SUM149PT lung colonies had a similar appearance, data not shown. Since induction of cell death, for example by apoptosis, could contribute significantly to the potency of systemic PhScN as an inhibitor of lung colonization, we assessed apoptosis induction in vitro in adherent SUM149PT cells by examining the effects of a 1-hour treatment with a range of Ac-PhScN-NH 2 concentrations. Figure 4D presents a typical Western blot indicating that PhScN does rapidly induce a dose-dependent upregulation of activated Caspase-3 in adherent SUM149PT cells; but concentrations required are 1,000-to 100,000-fold higher than those required for lung colonization inhibition. Effects of 500 -hSPNc-NH 2 per 10 6 SUM149PT cells, are also shown. The lack of activated Caspase-3 upregulation in SUM149PT cells treated with hSPNc demonstrates that although high PhScN concentrations are required for the upregulation of activated Caspase-3, the effect is sequence-specific.
Qualitatively, MDA-MB-231 and SUM149PT respond similarly to both PHSCN and PhScN; however, the corresponding IC 50 values are 10-to 100-fold higher for SUM149PT cells (Table 3 ). This may be due to the nature of the specific cell preparations or perhaps the differences between a metastatic cancer line (MDA-MB-231) and an inflammatory cell line (SUM149PT). Regardless of the IC 50 values, the overall DRI values determined for both MDA-MB-231 and SUM149PT cells suggest that PhScN is 1000-to 10,000-fold more potent at preventing lung colonization than PHSCN. Since stress, due to hypoxia for example, has been shown to increase activated receptor levels 25 , we checked whether Ac-PhScN-NH 2 treatment could induce apoptosis in breast cancer cells. We found that very elevated concentrations of (100, 200 and 300 g/ml) of Ac-PhScN-NH 2 could induce caspase-3 upregulation in adherent SUM149PT cells; but that lower levels (10 and 50 g/ml) had no effect, as shown in Figure 4D . 
Inhibition of bone metastasis progression by systemic PhScN therapy of mice after intratibial injection of metastatic human MDA-MB-231 breast cancer cells
In breast cancer, metastasis to the bone is usually an earlier disease event than lung colonization 26 . The interaction of bone-metastatic breast cancer cells with the surrounding bone marrow and matrix is best described by the "vicious cycle" model 27 . In this model, parathyroid hormone related protein (PTHrP) expressed by breast cancer cells after bone colonization 28 , stimulates progression and enhances osteoclastic bone resorption through its effects on osteoblasts 29, 30 ; moreover, it has been shown to enhance osteoclastic bone resorption in MDA-MB-231 bone metastases 31 . Furthermore, PTHrP is a key mediator of osteoclast activation 25 . In response to signals from metastatic breast cancer cells, bone lining osteoblasts express osteoclast-stimulatory factors, like receptor activator of nuclear kappa B ligand (RANKL) 32 , which stimulate osteoclast precursors to generate multinucleated osteoclasts 33 . These activated osteoclasts resorb mineralized bone matrix 34, 35 to release sequestered growth factors that promote metastatic growth by stimulating angiogenesis [36] [37] [38] . Activatedreceptors of microvascular endothelial cells interact with the PHSRN sequence of pFn cell-binding domain fragments to induce angiogenic invasion 5 . Furthermore, MDA-MB-231 colonies in the bones of athymic mice have been shown to induce angiogenesis in osteolytic metastases 39 . The identification of integrin as the primary integrin fibronectin receptor on human bone marrow stroma 40 suggests that PhScN could be effective in reducing bone metastases.
Microvascular endothelial cells (hmvec) were tested in our in vitro invasion assay as described 5 To assess the effects of PHSCN and PhScN on established bone metastases, DiI-labeled MDA-MB-231 cells were injected intratibially into athymic mice, and were allowed to grow into intra-osteal colonies for two weeks before thrice-weekly systemic treatments of 5 or 50 mg/kg of PhScN or PHSCN, respectively, were initiated. The MDA-MB-231 cells were not pretreated with either PhScN or PHSCN peptide prior to intratibial injection. Furthermore, mice received no systemic treatments of any kind for 2 weeks after intratibial injection. After 2 weeks of untreated intratibial MDA-MB-231 growth, systemic treatments were initiated. Treatments were continued for 24 days; with each mouse receiving a total of 10 systemic treatments. As shown in Fig. 5A, 50 
calculated DRI value indicates that PhScN is 25-fold more potent than PHSCN as a systemic inhibitor of bone metastasis progression.
As seen in the examples obtained from confocal microscopy, shown in Fig. 5C , few MDA-MB-231 cells remained in the intratibial bone marrow of mice treated with 50 mg/kg PhScN; whereas significantly more cells were present in the marrow of mice treated with 50 mg/kg PHSCN. As shown in the image from mice receiving 50 mg/kg PHSCN therapy, bone colonies appeared to be either extravascular, or closely associated with the vasculature. 
Colocalization of Ac-PhScNGGK-Bio with DiI in extravasated breast cancer cells
Since additional nodal metastases are identified in at least 20% of patients who undergo a completion axillary lymph node dissection (ALND) following a sentinel lymph node biopsy (SLNB) in which micrometastases were identified, the use of SLNB alone for staging the axilla may lead to the underestimation of the extent of nodal disease in 20% of cases 41 . Hence, a more efficient means of detecting bone-metastatic disease would be very beneficial. The potency of Ac-PhScN-NH 2 as a noncovalent inhibitor of -mediated invasion in vitro, as well as lung extravasation and metastasis, and bone colonization, suggested that the labeled PhScN peptide, Ac-PhScNGGK-Bio, might be an effective detection agent for extravasated, potentially metastatic breast cancer cells in sectioned biopsies. Thus, we assessed the ability of Ac-PhScNGGK-Bio to colocalize with DiI in lung-extravasated SUM149PT inflammatory breast cancer cells after they were -PhScNGGK-Bio peptide labeled 89% to 90% of extravasated SUM149PT cells in lung tissue sections of athymic mice, harvested 24 h after intravenous injection. Figure 6B shows representative images of detection of DiI-labeled SUM149PT, with and without colocalization of Ac-PhScNGGK-Bio. These results suggest that labeled PhScN could be an efficient agent for detecting extravasated breast cancer cells, which specifically express activated  integrin and hence are invasive and potentially metastatic. Since recurrent or metastatic disease develops in at least 40% of early breast cancer patients 42 , with bone metastasis occurring in most 27 , there is an urgent need for an effective, well-tolerated, therapy which can prevent both metastatic and angiogenic invasion. As summarized below in Scheme 1, the ability to inhibit activated  integrin receptors on metastatic breast cancer cells and their associated angiogenic, microvascular endothelial cells, may form the basis of an effective targeted therapy to inhibit the vicious cycle of breast cancer bone metastasis progression.
Overexpression of parathyroid hormone related protein, PTHrP, in MDA-MB-231 breast cancer cells has been shown to induce a 10-to 25-fold upregulation of  integrin promoter activity resulting in increased  integrin levels 43 . Furthermore, radiation has also been shown to stimulate invasion by inducing surface 13 upregulation of activated integrin 44 . Because integrin mediates metastatic invasion 4, 10, 12, 13, 45 to cause systemic dissemination 3,4 ,10 , as well as microvascular endothelial cell invasion 5 to promote angiogenesis, we have pursuedas a therapeutic target [3] [4] [5] [10] [11] [12] [13] 17 . Matrix metalloproteinase-1 (MMP1), is induced by the interaction of  integrin with the PHSRN sequence of the fibronectin cell binding domain 45 , and mediates both angiogenic and metastatic invasion by breast, prostate, and pancreatic cancer cells 3,4,5,10,,44, . MMP-1 has also been shown to activate the protease activated receptor-1 (PAR-1) gene in both breast cancer 46 and endothelial cells 47 , thereby promoting breast cancer invasion, as well as angiogenesis. PTHrP has been shown to stimulate osteoblasts to induce osteoclast progenitor differentiation into active osteoclasts, which mediate bone resorption, thereby releasing epidermal growth factor (EGF)-like growth factors to further stimulate bone metastasis progression 48 . Our research has shown that overexpression of receptor tyrosine-protein kinase erbB-2 or HER2, a member of the EGF receptor family, causes constitutive, serum-induced, pFn-dependent mediated invasion by immortalized mammary epithelial cells 49 , due to surface down regulation of the invasioninhibitory  fibronectin receptor 50 . The results of these studies thus suggest that inflammatory growth factors released as a result of bone resorption induce upregulation of activated  receptors to promote metastatic invasion of the bone, as well as angiogenic invasion to support bone colony progression. Hence, as summarized in Scheme 1, the  integrin fibronectin receptors of both bone-metastatic breast cancer cells and the microvascular endothelial cells of the bone marrow play a key role in the vicious cycle of bone metastasis. Scheme 1. 
Figure Legends

Specific Aim 3
Develop a mass spectrometry-based quantitative assay for PHSCN analogs, including PhScN, and evaluate their stabilities in human and mouse plasma.
Experimental design for quantitative assay of PHSCN analogs
An experimental approach based on mass spectrometric analysis to evaluate the stabilities of PHSCN analogs in human and mouse plasma has been designed as outlined below in Scheme 1. A known amount of target peptide is mixed with plasma and incubated at 37 °C for up to 24 hours. At specific incubation time points an aliquot is transferred to a small tube and protease reactions were quenched by adding three volumes of 50% acetonitrile with 0.5%TFA. Precipitated plasma proteins were removed by centrifugations, and a known amount of an internal standard was spiked into the supernatant containing the peptides, in order to increase the accuracy of quantitative measurements of LC-MS by reducing variances associated with sample preparations. MRFA (Met-Arg-Phe-Ala, monoisotopic molecular mass = 523.247.), a stable synthetic peptide with similar molecular mass to the target peptide, Ac-PHSCN-amide (monoisotopic molecular mass = 597.2328), is added into samples prior to LC-MS analysis. Stabilities of target peptides in plasma were evaluated by LC-MS.
Mass spectrometry
The LTQ-Orbitrap XL(Thermo Finnegan) connected to a 2D nanoLC(Exigent) and an autosampler in Andrews laboratory provides high mass resolution and accuracy for analytes separated on a capillary column at a flow rate of 200 nL/min, which assures confident identification of target molecules. Extracted peptides from plasma are reconstituted in 0.1% TFA and loaded into a C18 trap by autosampler and washed for 6 min at 5 microL/min with 0.1% TFA in water delivered by the LC loading pumps. Trapped peptides were introduced by switching valve into a capillary column (75 micro-m x 15 cm) custom-packed with C18 resin (3 micron) and separated over 60 min gradient at a flow rate of 200 nL/min. Analytes were introduced into the LTQ-Orbitrap via an electrospray device (Triversa Nanomate, Advion). MS and MSMS data were acquired in data-dependent mode for ions within 400-800 m/z. Figure 7 shows the total ion chromatogram (TIC) of LC-MSMS analysis of PHSCN and the internal standard MRFA. 
Quantitative assay of target peptides
Peptide quantification can be achieved by ion intensities in MS or by MSMS spectral counts in data-dependent acquisition mode. These two approaches are well established label-free quantification methods for peptides and proteins by LC-MSMS, which can be readily applied to a bioanalytical assay of therapeutic peptides. We are currently testing a new assay method, an MRM-like analysis via data-independent acquisition mode in the LTQ-Orbirap, in which ion packets within a mass range of 5 or 10 Da accumulated for a set time are co-fragmented.
One or multiple fragment ions specific to the target peptide can be monitored in MSMS based on highly accurate precursor ion mass and LC retention time. This MRM-like approach can provide a highly selective and sensitive bioanalytical assay under conditions of high chromatographic interference.
Study of collision-induced dissociation (CID) fragmentation of Ac-PHSCN-NH s in online LC-LTQ-Orbitrap
Ac-PHSCN-NH 2 introduced into the mass spectrometer via a nanoESI device (Triversa Nanomate) was predominantly observed as singly protonated form at 598.2328 m/z. However, in online LC-MS, the peptide was observed in doubly charged dimeric forms at 597.23 m/z and 589.23 m/z. The peptide dimer ions were characterized by CID that revealed disulfide-bond formation between two peptides that was catalyzed on C18 LC, as shown in a CID spectrum of 597.23 m/z. This is a potential source of interference with the assay that can be easily addressed by incorporating reduction and alkylation of the Cys residues into the protocol prior to LCMSMS although introduction of an additional step in the process could increase the variance slightly. The reason that dimerization occurs during the LC separation but not during other manipulations or assay approaches is not clear. 
KEY RESEARCH ACCOMPLISHMENTS:
1. Determination of invasion-inhibitory potencies for a total of 12 PHSCN and PhScN derivatives, targeting  integrin-mediated invasion of naturally serum-free basement membranes by 2 metastatic human breast cancer cell lines, SUM149PT and MDA-MB-231. Demonstration that covalent S-modification by several different moieties increases invasion-inhibitory potency by 100,000-to 1,000,000-fold, and that a 1,000,000-fold increase in potency is also obtained by substiution of D-His and D-Cys. These results demonstrate that the reason for the greatly increased invasion-inhibitory potency of PhScN is the suppression of covalent disulfide bond formation between the PHSCN sequence and its integrin target, and hence they are a key step in the determination of the PhScN target site on  integrin receptors of breast cancer cells.
Determination of invasion-inhibitory potencies of PHSCN and PhScN peptides, containing BPM-
derivatized cysteine or D-cysteine. The greatly increased invasion-inhibitory potencies of the BPMmodified PHSCN and PhScN peptides also confirm the noncovalent nature of invasion inhibition by the PhScN peptide.
Research accomplishments 1 and 2 complete Specific Aim 1 of the SOW. 3. Crosslinking with BPM-derivatized peptides, after integrin  activation with divalent cations, and analysis by Western blotting. Successful crosslinking with biotin labeled peptides, modified either at the cysteine or on the C-terminus, is anticipated to pave the way for protein enrichment and binding site identification by MS/MS. Our experiments demonstrating specific tagging of the integrin target indicate that significant scale-up will be required to obtain sufficient quantities for identification of the binding domains. 4. Determination of binding constants for PHSCNGGK-Bio and PhScNGGK-Bio on MDA-MB-231 and SUM149PT cells, and demonstration of their similarity provides the basis for acquiring information on any steric hindrances introduced by modification of the ligands not detected in functional invasion assays. 5. Demonstration that PHSCNGGK-Bio and PhScNGGK-Bio compete for the same binding site on SUM149PT and MDA-MB-231 cells. The results of these binding assays, in conjunction with the functional invasion inhibition results shown in Table 1 , will allow a more complete profile of the peptide ligand properties and their functional effects on  integrin-mediated invasion. Moreover, these results provide key support of the hypothesis that the increased potency of the PhScN peptide results from suppression of covalent, disulfide bond formation with the integrin target. Research accomplishments 3, 4, and 5 provide key support towards accomplishing Specific Aim 3 of the SOW. 6. Demonstration of CID fragmentation of Ac-PHSCN-NH 2 in online LC-LTQ-Orbitrap indicates that development of a mass spectrometry-based quantitative assay for PHSCN analogs, including PhScN, for the purpose of evaluating their stabilities in human and mouse plasma (Specific Aim 3) is feasible although the methods to suppress the formation of disulfide dimers during the separation procedure must be developed.
REPORTABLE OUTCOMES:
The following manuscript has been submitted for publication; and after review, a revised version is now under consideration by reviewers: Yao HY, Veine DM, and Livant DL (2015) Therapeutic Inhibition of Breast Cancer Bone Metastasis Progression and Lung Colonization: Breaking the Vicious Cycle by Targeting  Integrin.
CONCLUSION:
The PhScN peptide is a highly potent inhibitor of  integrin-mediated, serum-induced invasion because it suppresses covalent, disulfide bond formation with its target. Moreover, results of competition assays show that it targets the same region of  integrin as the PHSCN peptide parent.
